Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 5/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9528992 | 0.98 | ALDH1A1 (0.61) | ALDH1A1HPGDTSHRSMN1; SMN2RAB9A | |
| SCHEMBL211358 | 0.81 | RXFP1 (0.50) | ALDH1A1HPGDTSHRSMN1; SMN2RAB9A | |
| SCHEMBL1477812 | 0.79 | RAB9A (0.47) | ALDH1A1HPGDTSHRSMN1; SMN2RAB9A | |
| SCHEMBL3344131 | 0.79 | CNR1 (0.47) | ALDH1A1HPGDTSHRSMN1; SMN2RAB9A | |
| SCHEMBL3655946 | 0.79 | ALDH1A1 (0.61) | ALDH1A1HPGDTSHRSMN1; SMN2RAB9A | |
| SCHEMBL241856 | 0.79 | ALDH1A1 (0.61) | ALDH1A1HPGDTSHRSMN1; SMN2RAB9A | |
| SCHEMBL4883695 | 0.79 | ALDH1A1 (0.45) | ALDH1A1HPGDTSHRSMN1; SMN2RAB9A | |
| Bromide SCHEMBL6121613 | 0.79 | SMN1; SMN2 (0.49) | ALDH1A1HPGDTSHRSMN1; SMN2RAB9A | |
| SCHEMBL423145 | 0.79 | RAB9A (0.47) | ALDH1A1HPGDTSHRSMN1; SMN2RAB9A | |
| SCHEMBL15091637 | 0.79 | ALDH1A1 (0.61) | ALDH1A1HPGDTSHRSMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 631 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117925570-B | Method for extracting bioactive substances from placenta caprae seu ovis | 蚌埠学院 | 2025-04-22 | — | — | CN | claimed |
| CN-110167944-B | Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors | 联合疗法公司 | 2024-08-23 | — | — | CN | claimed |
| US-20200261383-A1 | PHARMACEUTICAL COMPOSITIONS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2020-08-20 | — | — | US | claimed |
| EP-3664780-A1 | PHARMACEUTICAL COMPOSITIONS | Kalvista Pharmaceuticals Limited (GB) | 2020-06-17 | — | — | EP | claimed |
| EP-2729443-B3 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LTD (GB) | 2020-02-12 | — | — | EP | claimed |
| US-10478409-B2 | Pharmaceutical compositions | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2019-11-19 | — | — | US | claimed |
| EP-2943181-B1 | PHARMACEUTICAL COMPOSITIONS | KALVISTA PHARMACEUTICALS LTD (GB) | 2019-04-10 | — | — | EP | claimed |
| US-20190070149-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2019-03-07 | — | — | US | claimed |
| WO-2019030540-A1 | PHARMACEUTICAL COMPOSITIONS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2019-02-14 | — | — | WO | claimed |
| CN-109122732-A | A kind of prevention and treatment ginger bacterial wilt of ginger combination sterilization composition | 重庆文理学院 | 2019-01-04 | — | — | CN | claimed |
| WO-2004089416-A2 | COMBINATION OF AN 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND AN ANTIHYPERTENSIVE AGENT | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | claimed |
| WO-2004089470-A2 | NEW AMIDE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | claimed |
| WO-2004089415-A2 | COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | claimed |
| US-6759412-B2 | FOR PRODUCING DRUGS USED FOR THERAPY OF CARDIOVASCULAR DISEASES, STABLE OR UNSTABLE ANGINA PECTORIS, CORONARY HEART DISEASE, PRINZMETAL ANGINA, ACUTE CORONARY SYNDROME, HEART FAILURE, MYOCARDIAL INFARCTION, STROKE, THROMBOSIS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-07-06 | — | — | US | claimed |
| CN-1491208-A | Acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amines and their use as pharmaceutical | ������ҽҩ�¹�����˾ | 2004-04-21 | — | — | CN | claimed |
| US-20040014766-A1 | Amide substituted xanthine derivatives | HOFFMANN-LA ROCHE INC. | 2004-01-22 | — | — | US | claimed |
| WO-2003106459-A1 | AMIDE SUBSTITUTED XANTHINE DERIVATIVES WITH GLUCONEOGENESIS MODULATING ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2003-12-24 | — | — | WO | claimed |
| EP-1362027-A2 | ACYLATED 6,7,8,9-TETRAHYDRO-5H-BENZOCYCLOHEPTENYL AMINES AND THEIR USE AS PHARMACEUTICAL | Aventis Pharma Deutschland GmbH (DE) | 2003-11-19 | — | — | EP | claimed |
| US-20030008915-A1 | Acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amines and their use as pharmaceutical agents | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-01-09 | — | — | US | claimed |
| WO-2002064546-A2 | ACYLATED 6,7,8,9-TETRAHYDRO-5H-BENZOCYCLOHEPTENYL AMINES AND THEIR USE AS PHARMACEUTICAL | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-08-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014766-A1 | Amide substituted xanthine derivatives | GYS2, GLS2, PYGL | ALDH1A1 297/4885HPGD 469/4885TSHR 1344/4885 |
| US-20190070149-A1 | PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR5A, HTR2A, HTR1A | ALDH1A1 953/4885HPGD 2403/4885TSHR 101/4885 |
| US-20200261383-A1 | PHARMACEUTICAL COMPOSITIONS | ADCY9, PDE6D, PDE6G | ALDH1A1 954/4885HPGD 2371/4885TSHR 685/4885 |
| US-20030008915-A1 | Acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amines and their use as pharmaceutical agents | VEGFA, NR1H2, EDNRA | ALDH1A1 343/4885HPGD 929/4885TSHR 871/4885 |
| US-10478409-B2 | Pharmaceutical compositions | PDE6D, ABCC9, PDE6H | ALDH1A1 475/4885HPGD 899/4885TSHR 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.